Bain Capital

HealthEdge provides a modern suite of products, HealthRules, built on patented technology. It enables healthcare payors to innovate, reduce costs, and improve outcomes by connecting everyone in the healthcare delivery cycle.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

HeartFlow specializes in precision heart care, offering a non-invasive solution for diagnosing coronary artery disease. Its proprietary HeartFlow FFRCT Analysis uses artificial intelligence to create a personalized 3D model of the heart, enabling clinicians to evaluate blood flow and determine optimal treatment. Commercially available in the United States, UK, Canada, Europe, and Japan.

Silna Health specializes in streamlining healthcare processes by offering a proactive care readiness platform. This platform ensures patients are eligible for care and handles prior authorizations, benefit checks, and insurance monitoring, thereby enhancing payment certainty and improving patient outcomes. It enables healthcare providers to expedite the process of scheduling appointments, from initial inquiry to booking, by managing these administrative tasks upfront.

Founded in 1992, CMIC Group specializes in providing Contract Research Organization (CRO) services for pharmaceutical companies. Based in Tokyo, Japan, the company offers a range of services including contract development and manufacturing, site management, and market services to facilitate faster drug development.

Charta Health is a technology company specializing in medical billing optimization. It employs artificial intelligence to scrutinize patient charts before claims are submitted, ensuring all potential revenue opportunities are captured, claim denials are minimized, and billing standards are consistently met. The platform offers real-time analytics, audits, and autonomous chart reviews, empowering healthcare professionals to enhance administrative efficiency and patient care.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company that develops and manufactures drugs for various indications, including immuno-inflammation, diabetes and kidney diseases, central nervous system disorders, vaccines, and over-the-counter products. Its portfolio includes Simponi for rheumatoid arthritis, Invokana for type 2 diabetes mellitus, Stelara for Crohn’s disease, Radicava for amyotrophic lateral sclerosis, Gilenya for multiple sclerosis, and Remicade for inflammatory autoimmune diseases. The company also offers vaccines such as influenza vaccine and Varicella vaccine.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Mayapada Hospital offers health and hospital management services. They provide a range of services ranging from diagnosis, therapy, surgery, and rehabilitation to comprehensive care and control of neurological disorders. They offer clinical services and medical consultations for digestive tract problems. Their paediatric centre also provides physical check-ups, vaccinations, and treatment for specific paediatric symptoms, heart failure, and orthopaedic disorders.

Angitia Biopharmaceuticals is a global clinical-stage biotechnology company focused on discovering and developing therapeutics for musculoskeletal diseases, specifically targeting bone, muscle, and joint conditions. Through its research and development activities, it aims to deliver breakthrough therapies that address unmet needs and improve outcomes for patients with severe musculoskeletal disorders.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Kailera Therapeutics is a biotechnology company focused on developing innovative treatments for obesity and associated conditions. It specializes in injectable and oral GLP-1 (Glucagon-like peptide-1) therapies, aiming to provide patients with transformative health solutions.

Founded in 2015, Imperative Care specializes in developing innovative medical technologies aimed at improving stroke treatment. Its flagship products include the Large Distal Platform catheter for deeper reach and the ZOOM Aspiration System for clot removal. The company's mission is to enhance treatment speed and effectiveness, ultimately optimizing patient recovery.

Kestra Medical Technologies develops and commercializes wearable medical devices and digital health solutions for cardiovascular care. The company provides monitoring, data collection, and therapeutic intervention to protect at-risk patients, with real-time and retrospective analysis. Its Cardiac Recovery System platform integrates monitoring, therapy, digital health tools, and patient support into a single solution, anchored by the ASSURE wearable cardioverter defibrillator designed to prevent sudden cardiac death and aid cardiac recovery. Kestra aims to transform patient outcomes in cardiovascular disease through intuitive, connected technologies.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

CereVasc, Inc. is a medical device company based in Auburndale, Massachusetts, specializing in the development of innovative, minimally invasive treatments for neurological diseases. The company has created the eShunt System, an endovascularly deliverable cerebrospinal fluid (CSF) shunt designed to replace traditional surgical methods for treating communicating hydrocephalus. This system aims to eliminate the need for invasive surgery, general anesthesia, and hospitalization, which are typically associated with the conventional use of ventriculo-peritoneal shunts. By providing a less invasive alternative, CereVasc seeks to improve patient outcomes and reduce the overall costs related to the surgical management of life-threatening neurological conditions. Established in 2014, CereVasc is focused on advancing healthcare solutions that enhance the treatment of various neurological brain disorders.

Sikich is a Chicago-based professional services firm offering expert business advisory services tailored to middle-market businesses. The company provides a range of services including accounting, audit, tax, and consulting services.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

1440 Foods develops and markets sports and active nutrition brands focused on protein and nutrition supplements. Its portfolio includes health and wellness brands, protein powders, meal replacements and lifestyle brands that support balanced nutrition and healthier living.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Aiolos Bio is a biotechnology company specializing in the development of therapies for respiratory diseases and immune conditions. Its primary focus is on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma, designed for dosing every 6 months. The company, founded by industry veterans, aims to address unmet treatment needs and improve patient outcomes by providing more efficacious and less burdensome therapies.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Silna Health specializes in streamlining healthcare processes by offering a proactive care readiness platform. This platform ensures patients are eligible for care and handles prior authorizations, benefit checks, and insurance monitoring, thereby enhancing payment certainty and improving patient outcomes. It enables healthcare providers to expedite the process of scheduling appointments, from initial inquiry to booking, by managing these administrative tasks upfront.

HeartFlow specializes in precision heart care, offering a non-invasive solution for diagnosing coronary artery disease. Its proprietary HeartFlow FFRCT Analysis uses artificial intelligence to create a personalized 3D model of the heart, enabling clinicians to evaluate blood flow and determine optimal treatment. Commercially available in the United States, UK, Canada, Europe, and Japan.

Estia Health is an Australian company that operates residential aged care facilities across several states, including Victoria, South Australia, New South Wales, and Queensland. The company focuses on providing quality aged care through specialized healthcare teams. Its facilities offer a range of services, including 24-hour nursing care, personal care, wound management, and physiotherapy, as well as accommodations for residents. Estia Health also facilitates external medical visits to ensure comprehensive care. A significant portion of its revenue is derived from funding provided by the Australian government.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Disclo is a HIPAA compliant platform enabling employers to collect, verify, and manage employee health disclosures and accommodation requests. Disclo helps employees secure the enhancements and protections they need to succeed in their careers without having to disclose their underlying medical condition to their employer.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on researching and developing transformative therapies for cardio-metabolic diseases. Founded in 2019 and based in Naarden, the Netherlands, it is developing obicetrapib, an oral, low-dose CETP inhibitor intended to lower LDL-C and potentially address statin intolerance or residual risk in patients with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy. The company aims to improve patient care in populations where approved therapies are inadequate or poorly tolerated.

Emalex Biosciences is a biotechnology startup focused on developing innovative treatments for central nervous system (CNS) disorders and rare neurological conditions. Founded in 2018 by Jeff Aronin, the company is advancing its lead candidate, Ecopipam, which has been explored as a potential therapy for various CNS disorders, including pediatric Tourette Syndrome and fluency disorders. Emalex aims to address the needs of patients with rare diseases that currently have limited or no treatment options, collaborating with patient advocacy organizations and medical researchers to facilitate the development of effective biopharmaceutical therapies.

Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health. It specializes in developing controlled metabolic accelerators (CMAs) to address the root metabolic risk factors associated with cardiovascular diseases.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Disclo is a HIPAA compliant platform enabling employers to collect, verify, and manage employee health disclosures and accommodation requests. Disclo helps employees secure the enhancements and protections they need to succeed in their careers without having to disclose their underlying medical condition to their employer.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

Classys specializes in manufacturing medical equipment.

Topography Health facilitates private practice physicians' involvement in clinical trials. It assists practices in understanding patient populations, recommends suitable studies, recruits patients, and manages research staff, making personalized clinical trials more accessible.

Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.

Linc'well is a health care technology company that provides a software as a service platform for medical institutions to streamline operations and improve efficiency. The platform handles appointments, communications, payments, and electronic medical records, supported by digitization services designed for clinics and hospitals. It also delivers clinic operation and management support through its CLINIC FORE brand and offers online support services such as medical supplement subscriptions. The company serves healthcare institutions and clinics, enabling providers to optimize patient experience and streamline administrative workflows. Founded in 2018 and based in Tokyo, Japan, Linc'well focuses on leveraging technology to reduce inefficiencies in healthcare delivery.

Athenahealth provides a range of internet-based services designed to enhance the operations of medical groups and health systems. The company offers a suite of solutions including athenaCollector for billing and practice management, athenaClinicals for electronic health record management, and athenaCommunicator for automated patient-provider communication. Additionally, it provides athenaCoordinator for care coordination, athenaTelehealth for telemedicine visits, and athenahealth Population Health, which focuses on managing population health data. The platform also features analytics and dashboard applications through athenaOne Analytics, as well as tools for clinical decision support and engagement through services like Epocrates. Athenahealth's integrated software and services aim to improve revenue cycle management, enhance patient engagement, and streamline healthcare operations, ultimately helping healthcare organizations achieve better financial and clinical outcomes. Founded in 1997 and headquartered in Watertown, Massachusetts, Athenahealth was taken private in 2019.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Founded in 2015, Imperative Care specializes in developing innovative medical technologies aimed at improving stroke treatment. Its flagship products include the Large Distal Platform catheter for deeper reach and the ZOOM Aspiration System for clot removal. The company's mission is to enhance treatment speed and effectiveness, ultimately optimizing patient recovery.

Feathery provides a low‑code platform that enables product teams to create and deploy data intake workflows, forms, and user journeys. It supports automatic deployment, SEO indexing, integration with popular frameworks and search engines, and is used by industries such as insurance, financial services, and healthcare to streamline data collection and improve control and speed.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

River 2 Renal is a developer of novel therapies intended to cure orphan diseases.

River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space. The company's technology has the potential to address the unmet need in several kidney diseases, by further improving the standard of care, enabling medical practitioners to treat patients in a better way. River 3 Renal was established in 2020 in New York, USA.

Multi-Specialty HealthCare operates more than 30 patient care centers throughout the Baltimore-Washington metropolitan area and the Delmarva Peninsula. It employs a patient-centric, integrated model focused on delivering high-quality care to individuals injured in automobile and workplace accidents, regardless of their health insurance status. The company has a team of general practice and urgent care physicians, chiropractors, orthopedists, and other medical specialists who provide a full spectrum of treatment including physical rehabilitation, medical care, and other ancillary services.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

AavantiBio, Inc. is a biopharmaceutical company focused on developing gene transfer and gene editing therapies aimed at treating rare genetic diseases. Incorporated in 2019 and based in Gainesville, Florida, the company primarily concentrates on Friedreich’s Ataxia, a rare inherited disorder that leads to significant cardiac and central nervous system dysfunction. AavantiBio is committed to transforming the lives of patients suffering from this condition by advancing innovative therapies that address unmet medical needs in the field of genetic disorders. The company’s efforts are directed toward both treatment development and research, with the goal of providing effective solutions for patients facing the challenges of rare diseases.

Hazel Health, Inc. is a healthcare company focused on enhancing student health and well-being by providing accessible healthcare services. Founded in 2015 and headquartered in San Francisco, California, the company offers a telehealth platform that allows K-12 students to connect with healthcare professionals through live video consultations, whether they are in school or at home. This innovative application enables students to receive timely medical attention for a variety of conditions, with the capability for doctors to prescribe over-the-counter medications at school, pending parental approval. By partnering with schools and their nursing staff, Hazel Health aims to ensure that every child has access to necessary pediatric care, thereby supporting their health and readiness to learn. The company was previously known as HippoMD, Inc. before rebranding in September 2017.

Kalderos, Inc. is a healthcare technology company that specializes in drug discount management solutions. Founded in 2016 and headquartered in Chicago, Illinois, with an additional location in Brookfield, Wisconsin, Kalderos offers a software-as-a-service (SaaS) platform designed to analyze and optimize the coordination of drug discount programs for healthcare providers, manufacturers, and payers. The platform employs advanced models and machine learning processes to identify and resolve non-compliance issues, detect inconsistencies, and provide data management capabilities. By offering features such as claims verification, dispute resolution, and discount monitoring, Kalderos enables its clients to streamline the communication and payment processes associated with drug discounts, ultimately eliminating waste and enhancing efficiency in the healthcare system.

Broadstep Behavioral Health specializes in providing a comprehensive range of behavioral health and supportive living services for individuals with intellectual and developmental disabilities (I/DD), mental illness, and co-occurring disorders. The organization serves over 1,300 individuals across 86 facilities in states including Wisconsin, North Carolina, New Jersey, Illinois, and South Carolina. Broadstep focuses on delivering physical, emotional, and mental support through various programs, including residential, educational, and vocational services. The aim is to create safe and nurturing environments where individuals feel valued and supported, fostering personal growth and community integration.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.

PresenceLearning, Inc. is a provider of online speech therapy, occupational therapy, behavioral and mental health services, and other special education-related resources for K-12 students and school districts across the United States and Canada. Founded in 2009 and based in San Francisco, the company utilizes a teletherapy platform that connects schools and parents with a network of licensed professionals through web-based videoconferencing technology. This platform allows for secure, live online sessions, enabling educational institutions to deliver evidence-based therapeutic activities and support to students with special needs. PresenceLearning has facilitated over 2.5 million teletherapy sessions, positioning itself as a leader in the delivery of clinical services via the internet.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Nurix Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing oral small-molecule therapies that modulate cellular protein levels to treat cancer and immune disorders. It operates DELigase, an integrated discovery platform that targets E3 ligases to alter protein abundance within cells. The company's product pipeline includes targeted protein degraders such as NX-2127, an oral Bruton's tyrosine kinase degrader for relapsed or refractory B-cell malignancies, and NX-1607, an oral Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications; these are in preclinical stages. Nurix also explores inhibitors of CBL-B, an E3 ligase that regulates T cell activation. The company collaborates with major industry partners, including Gilead Sciences and Sanofi, and was founded in 2009 and is headquartered in San Francisco.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Zelis is a healthcare and financial technology company that specializes in claims cost management and payments optimization solutions. Founded in 2016 and based in Bedminster, New Jersey, Zelis provides integrated services such as network analytics, payment integrity, electronic payments, and claims communications. These offerings aim to streamline the pricing, payment, and explanation of healthcare claims for payers, healthcare providers, and consumers across medical, dental, and workers' compensation markets. By leveraging advanced technology, Zelis assists its clients in navigating the complexities of the healthcare financial landscape while ensuring compliance with evolving regulations. The company is supported by investment firms Parthenon Capital Partners and Bain Capital.

Kestra Medical Technologies develops and commercializes wearable medical devices and digital health solutions for cardiovascular care. The company provides monitoring, data collection, and therapeutic intervention to protect at-risk patients, with real-time and retrospective analysis. Its Cardiac Recovery System platform integrates monitoring, therapy, digital health tools, and patient support into a single solution, anchored by the ASSURE wearable cardioverter defibrillator designed to prevent sudden cardiac death and aid cardiac recovery. Kestra aims to transform patient outcomes in cardiovascular disease through intuitive, connected technologies.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.

Founded in 2015, Imperative Care specializes in developing innovative medical technologies aimed at improving stroke treatment. Its flagship products include the Large Distal Platform catheter for deeper reach and the ZOOM Aspiration System for clot removal. The company's mission is to enhance treatment speed and effectiveness, ultimately optimizing patient recovery.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

IQVIA is a global leader in advanced analytics, technology solutions, and contract research services for the life sciences industry. It specializes in generating and analyzing large-scale health information to identify disease patterns and optimize treatment paths.

Kantar, a division of WPP, is a global leader in data-driven insights and consulting. With a team of 26,500 employees across 95 countries, Kantar unites diverse expertise in market research, analytics, and consulting to provide clients with comprehensive business insights. Its services span the entire consumer cycle, aiding clients in strategic decision-making. Kantar Health, a division of Kantar, specializes in data, analytics, and research for the life sciences industry, helping clients bring safe and effective treatments to patients worldwide.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

LunaDNA is a community-owned genomic and medical research platform founded by the creators of a leading DNA sequencing company. It facilitates the sharing of health and DNA data, allowing individuals to contribute their personal information for medical research while maintaining ownership of their data. By incentivizing participation, LunaDNA addresses the challenge of data silos that have emerged as personal DNA sequencing has gained popularity. Participants are rewarded with shares in the database, granting them a stake in the profits generated from medical research. These profits are returned to the community as dividends when researchers pay for access to the data. LunaDNA empowers individuals to support health research while ensuring that their contributions benefit the broader community and drive medical discoveries.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

ImageMoverMD is a medical imaging software company that integrates enterprise imaging and electronic health record systems. The company's innovative solutions employ an exclusive approach to securely connect photos, video, and outside medical images with the EHR, simplifying communication, and enhancing patient care. It transforms enterprise imaging to improve the quality and cost of care while optimizing patient and provider experience. ImagerMoverMD using web-native automation applications that integrate with both the EMR and the VNA/PACs systems, the ImageMover platform measurably improves efficiency, increases revenue capture, and drives HIPAA compliance across the entire care continuum. It also provides end-to-end imaging optimization for health systems.

nData is an IT firm specialized in development of applications for pharma companies and CRO’s.

Centric Health offers an innovative approach to primary healthcare in Ireland, the UK, and Australia, focusing on keeping patients healthy within their communities. The company provides a wide range of accessible medical services that traditionally would have required hospital visits, including community general practice clinics, urgent care facilities, diagnostic imaging centers, and occupational health services. By addressing local healthcare needs proactively, Centric Health aims to enhance patient care and treatment for chronic conditions, ensuring that patients are at the center of their operations.

Sansoro Health, Inc. is a healthcare technology company based in Minneapolis, Minnesota, that specializes in integration software for electronic medical record (EMR) platforms. Founded in 2014, the company offers its flagship product, Emissary, which facilitates EMR interoperability through universal application programming interfaces (APIs) and a unified data model. Emissary allows for the integrated display of patient charts from multiple EMRs, enabling real-time clinical analytics alongside web portals and mobile applications. This middleware can be quickly implemented, often within hours, and connects seamlessly with existing EMR systems, significantly reducing costs and operational challenges for healthcare providers. Additionally, Sansoro Health provides tools for monitoring and managing the integration environment, which include advanced security and auditing features, ensuring a streamlined data exchange between electronic health records and clinical administrative applications.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Iodine Software LLC, founded in 2010 and based in Austin, Texas, develops advanced artificial intelligence-based software solutions aimed at enhancing clinical documentation integrity for hospitals across the United States. The company's AwareCDI™ Suite leverages machine learning algorithms to analyze extensive clinical data and documentation, providing predictive insights that assist clinicians and hospital administrators in automating complex tasks. By improving the accuracy and efficiency of clinical documentation, Iodine Software empowers healthcare providers to deliver better patient care while optimizing operational performance. With nearly 500 hospitals utilizing its technology, the company plays a significant role in the transformation of healthcare documentation practices.

InflaRx is a biopharmaceutical company focused on developing novel therapeutics targeting acute and chronic inflammation. Founded by internationally recognized researchers, the company specializes in applying proprietary anti-C5a/C5aR technology to create first-in-class inhibitors of complement activation factor C5a and its receptor C5aR.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.

AbleTo is a leading provider of virtual behavioral healthcare services in the United States. It uses an integrated proprietary platform to identify and engage individuals with unmet behavioral health needs, connecting them with licensed therapists/coaches nationwide. AbleTo's tele-behavioral health programs improve clinical outcomes for patients with conditions such as depression, anxiety, stress, heart disease, diabetes, and chronic pain.

Halo Health Inc. is a technology company that specializes in providing clinical communication and care coordination solutions for healthcare organizations in the United States. The company offers a comprehensive clinical communication platform that includes various tools such as secure messaging for healthcare professionals, an enterprise-wide scheduling system, and patient engagement features. Its offerings, which include Halo Messaging, Halo Pronto, Patient Halo, Halo Handoff, Halo Link, and Halo Patient Coordinator, aim to enhance real-time communication among physicians, nurses, and staff, thereby streamlining patient care. The platform integrates seamlessly with hospital systems, allowing users to access electronic health records, manage on-call schedules, and coordinate care effectively. Halo Health's solutions are designed to improve response times, reduce readmission rates, and facilitate efficient transitions of care. Founded in 2010 and headquartered in Cincinnati, Ohio, Halo Health was previously known as Doc Halo, LLC until it rebranded in May 2018.

Hugel, Inc. is a biopharmaceutical company based in Chuncheon-si, South Korea, specializing in the development and manufacturing of innovative medical products. The company offers a range of Botulinum Toxin products under various brand names, including Botulax and Hugel Toxin, for medical applications such as treating eyelid convulsions, severe wrinkles, upper limb stroke, and specific foot deformities in children. Additionally, Hugel produces hyaluronic acid fillers marketed under brands like Dermalax and Revigance, as well as cosmetics under the Wellage brand. The company is committed to enhancing global health and quality of life through advanced technology and creativity, operating manufacturing facilities in Shinbuk and Geodu. Founded in 2001, Hugel aims to expand its international presence in the biopharmaceutical sector.

Sansoro Health, Inc. is a healthcare technology company based in Minneapolis, Minnesota, that specializes in integration software for electronic medical record (EMR) platforms. Founded in 2014, the company offers its flagship product, Emissary, which facilitates EMR interoperability through universal application programming interfaces (APIs) and a unified data model. Emissary allows for the integrated display of patient charts from multiple EMRs, enabling real-time clinical analytics alongside web portals and mobile applications. This middleware can be quickly implemented, often within hours, and connects seamlessly with existing EMR systems, significantly reducing costs and operational challenges for healthcare providers. Additionally, Sansoro Health provides tools for monitoring and managing the integration environment, which include advanced security and auditing features, ensuring a streamlined data exchange between electronic health records and clinical administrative applications.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Diversey is a global manufacturer specializing in cleaning, hygiene, and infection prevention products. It serves a wide range of institutional markets, including lodging, food service, retail, healthcare, and food processing facilities, as well as building service contractors worldwide. The company's portfolio comprises high-performance solutions for various applications such as dishwashing, surface cleaning, floor care, laundry, and hand hygiene. Additionally, Diversey offers value-added services like training, consulting, and auditing to ensure optimal hygiene and food safety. The company generates the majority of its revenue from Europe, followed by North America, Asia Pacific, and other regions.

Craigcare Group is a leading provider of residential accommodation services for seniors in Western Australia, dedicated to creating a supportive environment for older Australians requiring assistance with daily living tasks. Established in 2002 and headquartered in Ardross, the company operates a nursing home that offers a range of health and wellness services, including podiatry, dietician consultations, physiotherapy, hairdressing, occupational therapy, and speech pathology. In addition to these services, Craigcare provides various recreational activities such as exercise programs, board games, cultural events, live music, and woodworking groups. The company also manages a retirement village in Albany, offering permanent, respite, dementia, and palliative care services to ensure comfort and dignity for its residents during their later years.

Epic Health Services is a prominent provider of home health care, specializing in services for medically fragile children. The company offers a range of pediatric skilled nursing and therapy services, including personal care, behavioral health nursing, and developmental services. In addition to its focus on pediatric care, Epic Health Services also provides various adult home health care services, ensuring comprehensive support for individuals of all ages. Through its dedicated approach, the company aims to enhance the quality of life for its patients and their families.

Navicure’s cloud-based healthcare claims management and patient payment solutions help healthcare organizations of all sizes increase revenue, accelerate cash flow, and reduce costs associated with managing insurance claims and patient payments. Serving more than 90,000 healthcare providers nationwide, Navicure’s technology solutions automate account receivables processes, including claims management; patient eligibility verification; remittance and denial management including automated secondary claims filing, appeals, and posting; reporting and analysis; and patient payment collections at and near the time of service. Navicure’s solutions are supported by its unique 3-Ring® Client Service which guarantees that a client service representative will answer every client call in three rings or less. Navicure is the exclusive billing and patient payment solution of the MGMA Executive Partner network.

Apixio, Inc. is a data science company specializing in healthcare solutions through its cognitive computing platform. Founded in 2009 and based in San Mateo, California, Apixio provides a range of applications including HCC Profiler, a software-as-a-service tool that leverages the Iris platform to analyze medical charts and Medicare-reported chronic condition data for more accurate patient risk scoring than traditional methods. Additionally, the company offers Quality Identifier, which enables health plans and providers to extract critical patient insights to enhance quality measurement and care delivery. Its Compliance Auditor solution helps insurers verify the accuracy of their risk adjustment coding, while its AI-powered tools support internal audits of risk adjustment payments. By integrating centralized patient health profiles and data-driven insights, Apixio aims to streamline operations for healthcare organizations, ensuring accurate payments and supporting the transition to value-based reimbursement models.

Asia Pacific Medical Group operates hospitals and healthcare clinics that deliver a range of medical services to patients in China, Southeast Asia, and beyond. Founded in 1992 by a group of 35 American physicians and surgeons, the organization has rapidly expanded to include 22 clinics and 7 hospitals, establishing itself as a prominent international healthcare provider in the region. The services offered include gamma-knife treatments, neurology and neurosurgery, non-invasive cosmetic dermatology, plastic surgery, and intensity-modulated radiation therapy for various types of tumors, such as those affecting the brain, head and neck, lungs, esophagus, breasts, liver, pancreas, and prostate. Headquartered in Causeway Bay, Hong Kong, Asia Pacific Medical Group is dedicated to providing quality healthcare while ensuring affordability for its patients.